A Pilot, Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Disseminated Mycobacterium Avium Complex Disease (MAC) in AIDS Patients Who Are Receiving Standard Acute Treatment for This Opportunistic Infection
A Pilot, Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Disseminated Mycobacterium Avium Complex Disease (MAC) in AIDS Patients Who Are Receiving Standard Acute Treatment for This Opportunistic Infection
The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are being treated for MAC.
Inclusion Criteria
Patients must have:
Prior Medication:
Allowed:
Patients no more than 7 days of therapy for MAC disease.
Exclusion Criteria
Prior Medication:
Excluded:
Prior therapy (or less than 2 weeks) with protease inhibitors other than saquinavir.